Peter Guzzo, PhD, CEO and Co-founder

Dr. Guzzo brings over 20 years of drug discovery and development leadership to ConSynance. He enjoys building entrepreneurial teams and has been involved in the technology transfer and licensing of multiple projects. He previously led large teams of scientists at Albany Molecular Research, Inc. as part of an international R&D effort. He was responsible for the management and strategic planning for an innovative pipeline which included metabolic, CNS (psychiatric diseases), and gastrointestinal disease projects that produced four clinical compounds and multiple candidate compounds. He has published over 40 papers in peer-reviewed journals, is an inventor on over 40 US patents/applications and regularly presents at scientific conferences. Pete holds a PhD in Organic Chemistry from University of Notre Dame and conducted postdoctoral training at Rensselaer Polytechnic Institute.

Shuang Liu, PhD, President and Co-founder

Prior to co-founding ConSynance in 2015, Dr. Liu had 15-year experience leading a number of integrated drug discovery programs for both AMRI’s internal R&D efforts and clients in CNS, metabolic, oncology and autoimmune diseases. Her teams discovered multiple compounds which advanced into clinical development. She is the co-inventor of more than 30 US patents/applications and co-author of 18 peer reviewed articles. Shuang holds a BS in chemistry from Beijing Normal University and PhD in Organic Chemistry from University of Georgia. She completed her post-doctoral training at Emory University.

Wayne Boomer, CPA, Interim Chief Financial Officer

Mr. Boomer has over 20 years of finance and operations experience working within both publicly traded and venture backed technology companies. He initially worked multiple years for one of the “Big 4” accounting firms and as a senior associate obtaining his CPA. He worked for over 8 years in publicly traded companies in senior finance positions and was the CFO of On2 Technology, which was the first publicly traded company acquired by Google. In 3 of the 4 companies Mr. Boomer held senior finance and operations positions were ultimately acquired as they were built for growth and success resulting in material returns to shareholders.

Philip Perera MD, MBA, Medical Advisor

Dr. Perera has over 20 years clinical and research experience and has been responsible for the development and approval of small molecule drugs for a variety of CNS and pain disorders. Phil has held senior level clinical, scientific, management and business development positions such as CMO, Medical Director and VP at Dart NeuroScience, GSK, Pharmacia Upjohn, Jazz Pharmaceuticals, Pfizer and the Parkinson's Institute. Prior to working in the pharmaceutical industry, he was on the faculty of New York Hospital, Cornell Medical College and North Shore University Hospital, and he was a practicing adult and geriatric psychiatrist. He has published numerous clinical research papers. He holds an MD from Harvard Medical School and is a board-certified Psychiatrist. He also holds an MBA from Arizona State University.

James Kuo, MD, MBA, Business Strategy Advisor

Dr. Kuo is the Managing Director of Athena Bioventures. He has extensive experience in the life science industry as a Chief Executive Officer, business development executive, and venture capitalist. He is a serial entrepreneur with several publicly traded and private companies. Jim holds a MD from University of Pennsylvania School of Medicine and MBA from The Wharton School of Business.